Metastatic urothelial carcinoma harboring ERBB2/3 mutations dramatically respond to chemotherapy plus anti-PD-1 antibody: A case report

BACKGROUND: Immune checkpoint inhibitors (ICIs) targeting the programmed death (PD)-1 pathway have substantially changed the clinical management of metastatic urothelial carcinoma (mUC); however, the response rate remains low. There are ongoing efforts to identify robust biomarkers that can effectiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Yan, Fei-Fei, Jiang, Qi, Ru, Bin, Fei, Xiao-Jie, Ruan, Jian, Zhang, Xiao-Chen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8968593/
https://www.ncbi.nlm.nih.gov/pubmed/35434068
http://dx.doi.org/10.12998/wjcc.v10.i8.2497

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8968593/
https://www.ncbi.nlm.nih.gov/pubmed/35434068
http://dx.doi.org/10.12998/wjcc.v10.i8.2497

Ejemplares similares